Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes.

Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, Trautmann M

Diabetes care23 Mar 2010Cited by 172 (Europe PMC)

PMID20332357PMCIDPMC2875418DOI10.2337/dc09-1203PepBankPUB-20332357

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialEfficacy outcome
In nondiabetic obese subjects receiving lifestyle intervention, exenatide reduced weight more than placebo.
In plain wordsIn people with obesity without diabetes, exenatide reduced weight more than placebo during lifestyle intervention.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight change
Study
n = 152
Comparator
placebo plus lifestyle intervention
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
Weight loss
5.1 kg
exenatide
Weight loss
1.6 kg
placebo
Placebo-subtracted percent weight change
−3.3%
exenatide
Source sentences
Summary
RESULTS Exenatide-treated subjects lost 5.1 +/- 0.5 kg from baseline versus 1.6 +/- 0.5 kg with placebo (exenatide--placebo, P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Placebo-subtracted difference in percent weight reduction was -3.3 +/- 0.5% (P < 0.001).
Summary · context
Obese subjects (n = 152; age 46 +/- 12 years, female 82%, weight 108.6 +/- 23.0 kg, BMI 39.6 +/- 7.0 kg/m(2), IGT or IFG 25%) were randomized to receive exenatide (n = 73) or placebo (n = 79), along with lifestyle intervention, for 24 weeks.
Report a problemFND-2033235701
02HumanRandomized controlled trialEfficacy outcome
In obese subjects with IGT or IFG, normalization occurred in 77% with exenatide and 56% with placebo.
In plain wordsIn people with obesity and abnormal glucose tolerance, glucose normalized more often with exenatide than placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseNormalization of IGT or IFG
Study
n: not reported in source
Comparator
placebo plus lifestyle intervention
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
Normalization
77%
exenatide
Normalization
56%
placebo
Source sentences
Summary
IGT or IFG normalized at end point in 77 and 56% of exenatide and placebo subjects, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Obese subjects (n = 152; age 46 +/- 12 years, female 82%, weight 108.6 +/- 23.0 kg, BMI 39.6 +/- 7.0 kg/m(2), IGT or IFG 25%) were randomized to receive exenatide (n = 73) or placebo (n = 79), along with lifestyle intervention, for 24 weeks.
Report a problemFND-2033235703

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

03HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In nondiabetic obese subjects receiving lifestyle intervention, calorie intake decreased in both exenatide and placebo groups.
In plain wordsIn people with obesity without diabetes, calorie intake decreased with both exenatide and placebo during lifestyle intervention.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseDaily calorie intake
Study
n = 152
Comparator
placebo plus lifestyle intervention
Outcome group
Appetite and food intake · Metabolic and weight
Measurements
Calorie intake change
−449 cal
exenatide
Calorie intake change
−387 cal
placebo
Source sentences
Summary
Both groups reduced their daily calorie intake (exenatide, -449 cal; placebo, -387 cal).
1 context sentence(design, population, supporting numbers)
Summary · context
Obese subjects (n = 152; age 46 +/- 12 years, female 82%, weight 108.6 +/- 23.0 kg, BMI 39.6 +/- 7.0 kg/m(2), IGT or IFG 25%) were randomized to receive exenatide (n = 73) or placebo (n = 79), along with lifestyle intervention, for 24 weeks.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2033235702

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableResults postedNCT01444898

Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome

Children's Hospital Los Angelesn = 10Mar 2012 to Dec 2013

Prader-Willi Syndrome

Trial page ClinicalTrials.govUpdated 29 Sept 2016

CompletedPhase 2Results postedNCT00500370

A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients

AstraZenecan = 163Jun 2007 to Feb 2008

Obesity

Trial page ClinicalTrials.govUpdated 7 Apr 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.